Development_NN of_IN a_DT Yeast_NP Assay_NP for_IN Rapid_NP Screening_NP of_IN Inhibitors_NP of_IN Human-Derived_NP Pneumocystis_NP carinii_NP Dihydrofolate_NP Reductase_NP Human-derived_NP Pneumocystis_NP carinii_NP dihydrofolate_JJ reductase_NN (_( DHFR_NP )_) was_VBD expressed_VBN in_IN a_DT Saccharomyces_NP cerevisiae_NNS strain_NN whose_WP$ growth_NN depends_VBZ on_IN complementation_NN by_IN this_DT enzyme_NN ._SENT We_PP utilized_VBD a_DT quantitative_JJ assay_NN to_TO measure_VB the_DT sensitivity_NN of_IN this_DT yeast_NN strain_NN to_TO DHFR_NP inhibitors_NNS ._SENT This_DT assay_NN should_MD be_VB useful_JJ for_IN identifying_VBG new_JJ inhibitors_NNS of_IN human-derived_JJ P._NP carinii_NP DHFR_NP ._SENT Current_JJ treatment_NN of_IN Pneumocystis_NP carinii_NP pneumonia_NN (_( PCP_NP )_) is_VBZ complicated_VBN by_IN frequent_JJ toxic_JJ and_CC allergic_JJ side_NN effects_NNS ,_, emerging_VBG drug_NN resistance_NN ,_, and_CC limited_JJ therapeutic_JJ options_NNS ._SENT There_EX is_VBZ a_DT clear_JJ need_NN to_TO discover_VB new_JJ agents_NNS against_IN P._NP carinii_NP ._SENT Dihydrofolate_JJ reductase_NN (_( DHFR_NP )_) is_VBZ a_DT well-described_JJ target_NN for_IN antimicrobial_JJ chemotherapy_NN ,_, and_CC its_PP$ inhibitors_NNS ,_, like_IN trimethoprim_NP ,_, pyrimethamine_NN ,_, and_CC trimetrexate_NP ,_, are_VBP commonly_RB used_VBN drugs_NNS for_IN PCP_NP therapy_NN or_CC prophylaxis_NN ._SENT Genes_NNS encoding_VBG DHFR_NP of_IN P._NP carinii_NP from_IN various_JJ mammalian_JJ host_NN species_NNS have_VBP been_VBN cloned_VBN ._SENT The_DT amino_NN acid_NN sequence_NN of_IN DHFR_NP of_IN human-derived_JJ P._NP carinii_NP differs_VBZ from_IN that_IN of_IN rat-derived_JJ P._NP carinii_NP by_IN 38_CD %_NN ,_, with_IN some_DT of_IN the_DT amino_NN acid_NN changes_NNS occurring_VBG in_IN the_DT active_JJ sites_NNS of_IN the_DT enzyme_NN ._SENT Thus_RB ,_, the_DT ideal_JJ target_NN for_IN designing_VBG potential_JJ antifolate_JJ drugs_NNS for_IN the_DT treatment_NN of_IN humans_NNS is_VBZ human-derived_JJ P._NP carinii_NP DHFR_NP ._SENT The_DT expression_NN of_IN recombinant_JJ human-derived_JJ P._NP carinii_NP DHFR_NP enzyme_NN has_VBZ permitted_VBN kinetic_JJ characterization_NN of_IN the_DT enzyme_NN and_CC reassessment_NN of_IN the_DT inhibitory_JJ potency_NN of_IN several_JJ commonly_RB used_VBN antifolate_JJ drugs_NNS by_IN in_IN vitro_NN enzyme_NN assays_NNS ._SENT The_DT goal_NN of_IN the_DT present_JJ study_NN was_VBD to_TO develop_VB a_DT rapid_JJ ,_, complementation-based_JJ drug_NN screening_NN system_NN by_IN using_VBG the_DT yeast_NN Saccharomyces_VBZ cerevisiae_NNS expressing_VBG human-derived_JJ P._NP carinii_NP DHFR_NP ,_, as_RB has_VBZ been_VBN previously_RB reported_VBN for_IN other_JJ organisms_NNS ._SENT The_DT yeast_NN model_NN system_NN used_VBN in_IN this_DT study_NN was_VBD derived_VBN from_IN an_DT S._NP cerevisiae_NNS strain_NN (_( TH5_NP ;_: Mataura3-52_NP leu2-3,112_JJ trp1_JJ tup1_JJ dfr1::URA3_NN )_) (_( kindly_RB provided_VBN by_IN Carol_NP Hopkins_NP Sibley_NP )_) in_IN which_WDT the_DT endogenous_JJ DHFR_NP gene_NN is_VBZ inactivated_VBN ._SENT The_DT human-derived_JJ P._NP carinii_NP DHFR_NP coding_VBG region_NN was_VBD amplified_VBN by_IN PCR_NP from_IN a_DT plasmid_NN we_PP constructed_VBD previously_RB ,_, cloned_VBN into_IN an_DT expression_NN vector_NN containing_VBG S._NP cerevisiae_NNS sequences_NNS that_WDT permit_VBP replication_NN of_IN the_DT plasmid_NN and_CC expression_NN of_IN a_DT heterologous_JJ gene_NN in_IN yeast_NN ._SENT and_CC transformed_VBN into_IN TH5_NP cells_NNS by_IN the_DT lithium_NN acetate_NN method_NN ._SENT The_DT transformants_NNS were_VBD selected_VBN on_IN plates_NNS containing_VBG tryptophan-deficient_JJ synthetic_JJ medium_NN supplemented_VBN with_IN 100_CD mug_NN of_IN dTMP_NN (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) per_IN ml_NN and_CC plated_VBN on_IN rich_JJ yeast_NN extract-peptone-dextrose_NN medium_NN without_IN dTMP_NN to_TO test_VB the_DT function_NN of_IN the_DT construct_NN ._SENT TH5_JJ yeast_NN strains_NNS expressing_VBG rat-derived_JJ P._NP carinii_NP DHFR_NP or_CC human_JJ DHFR_NP have_VBP been_VBN described_VBN previously_RB ._SENT To_TO determine_VB the_DT sensitivity_NN of_IN the_DT engineered_JJ yeasts_NNS to_TO several_JJ selected_JJ antifolate_JJ drugs_NNS ,_, assays_NNS of_IN the_DT concentration_NN of_IN the_DT drug_NN required_VBN to_TO inhibit_VB cell_NN growth_NN by_IN 50_CD %_NN (_( IC50_NP assays_NNS )_) were_VBD conducted_VBN with_IN 1_CD mM_NP sulfanilamide_NN ,_, as_RB previously_RB described_VBN ._SENT Each_DT drug_NN was_VBD tested_VBN in_IN triplicate_NN in_IN at_IN least_JJS two_CD separate_JJ experiments_NNS ._SENT Figure_NP and_CC Table_NP illustrate_VBP the_DT inhibition_NN patterns_NNS of_IN selected_JJ DHFR_NP inhibitors_NNS for_IN different_JJ yeast_NN strains_NNS ._SENT For_IN the_DT human-derived_JJ P._NP carinii_NP DHFR_NP yeast_NN strain_NN ,_, trimethoprim_NP and_CC pyrimethamine_NN were_VBD both_DT weak_JJ inhibitors_NNS ,_, with_IN IC50s_NP in_IN the_DT micromolar_JJ range_NN ;_: trimetrexate_NP was_VBD about_RB 10-fold_JJ and_CC 40-fold_JJ more_JJR potent_JJ than_IN trimethoprim_NP and_CC pyrimethamine_NN ,_, respectively_RB ._SENT WR99210_NP ,_, a_DT triazine_NN compound_NN (_( Jacobus_NP Pharmaceutical_NP Company_NP ,_, Princeton_NP ,_, N.J._NP )_) ,_, has_VBZ been_VBN found_VBN to_TO be_VB highly_RB effective_JJ against_IN malaria_NN DHFR_NP but_CC has_VBZ not_RB been_VBN tested_VBN for_IN activity_NN against_IN human-derived_JJ P._NP carinii_NP DHFR_NP ._SENT WR99210_NP was_VBD an_DT even_RB more_RBR potent_JJ inhibitor_NN ,_, with_IN an_DT IC50_NN in_IN the_DT 10-8_CD M_NP range_NN ._SENT In_IN comparison_NN with_IN the_DT rat-derived_JJ P._NP carinii_NP DHFR_NP strain_NN ,_, the_DT human-derived_JJ P._NP carinii_NP DHFR_NP strain_NN showed_VBD very_RB similar_JJ sensitivities_NNS to_TO pyrimethamine_NN and_CC WR99210_NP but_CC was_VBD about_RB 10-fold_NN more_RBR sensitive_JJ to_TO both_DT trimethoprim_NP and_CC trimetrexate_NP ._SENT WR99210_NP exhibited_VBD excellent_JJ selectivity_NN for_IN both_DT human-_NN and_CC rat-derived_JJ P._NP carinii_NP DHFRs_NN compared_VBN to_TO that_DT for_IN human_JJ DHFR_NP ._SENT While_IN trimethoprim_NP showed_VBD a_DT relatively_RB favorable_JJ selectivity_NN ,_, trimetrexate_NN and_CC pyrimethamine_NN appeared_VBD not_RB to_TO be_VB selective_JJ in_IN this_DT assay_NN system_NN ._SENT Table_NN shows_VBZ a_DT comparison_NN between_IN the_DT IC50s_NP from_IN the_DT yeast_NN assay_NN and_CC those_DT from_IN an_DT in_IN vitro_NP enzyme_NN assay_NN ,_, based_VBN upon_IN previously_RB published_VBN data_NNS (_( for_IN trimethoprim_NP ,_, pyrimethamine_NN ,_, and_CC trimetrexate_NP )_) or_CC data_NNS generated_VBN in_IN this_DT study_NN by_IN using_VBG previously_RB described_VBN methods_NNS and_CC conditions_NNS (_( WR99210_NP )_) ._SENT Based_VBN on_IN three_CD experiments_NNS ,_, the_DT mean_JJ IC50_NP (_( +-_NN standard_NN deviation_NN )_) of_IN WR99210_NP for_IN human-derived_JJ P._NP carinii_NP DHFR_NP was_VBD 10.0_CD (_( +-1.0_NN )_) nM_NN ._SENT A_DT comparison_NN of_IN the_DT relative_JJ inhibition_NN profiles_NNS in_IN the_DT yeast_NN assay_NN and_CC those_DT in_IN the_DT in_IN vitro_NN assay_NN supports_VBZ the_DT usefulness_NN of_IN the_DT yeast_NN assay_NN as_IN an_DT initial_JJ step_NN for_IN identifying_VBG new_JJ inhibitors_NNS of_IN human-derived_JJ P._NP carinii_NP DHFR_NP ._SENT The_DT yeast_NN assay_NN is_VBZ simple_JJ ,_, fast_RB ,_, and_CC inexpensive_JJ and_CC could_MD readily_RB be_VB adapted_VBN for_IN automation_NN ._SENT The_DT usefulness_NN of_IN this_DT system_NN in_IN screening_NN for_IN antimicrobial_JJ drugs_NNS has_VBZ been_VBN well_RB demonstrated_VBN in_IN previous_JJ studies_NNS ._SENT The_DT IC50_NP obtained_VBD by_IN the_DT yeast_NN assay_NN is_VBZ the_DT result_NN of_IN a_DT complex_JJ function_NN of_IN the_DT level_NN of_IN expression_NN of_IN the_DT target_NN enzyme_NN in_IN the_DT yeast_NN ,_, the_DT penetration_NN of_IN the_DT drug_NN to_TO the_DT cellular_JJ location_NN of_IN the_DT target_NN enzyme_NN ,_, and_CC the_DT intrinsic_JJ ability_NN of_IN the_DT drug_NN to_TO inhibit_VB the_DT enzyme_NN ._SENT Furthermore_RB ,_, the_DT addition_NN of_IN 1_CD mM_NP sulfanilamide_NN in_IN the_DT yeast_NN assay_NN will_MD also_RB inhibit_VB ,_, to_TO some_DT extent_NN ,_, the_DT growth_NN of_IN the_DT yeast_NN cells_NNS ._SENT Therefore_RB ,_, the_DT actual_JJ IC50_NN in_IN the_DT yeast_NN assay_NN cannot_MD be_VB compared_VBN directly_RB with_IN that_DT obtained_VBN from_IN an_DT in_IN vitro_NN assay_NN ,_, which_WDT reflects_VBZ a_DT direct_JJ interaction_NN between_IN the_DT drug_NN and_CC the_DT target_NN enzyme_NN under_IN standardized_JJ conditions_NNS ._SENT As_IN shown_VBN in_IN Table_NP ,_, the_DT absolute_JJ IC50s_NN of_IN the_DT four_CD drugs_NNS tested_VBN showed_VBD some_DT differences_NNS between_IN the_DT two_CD assay_NN systems_NNS ._SENT In_IN a_DT given_VBN recombinant_JJ strain_NN ,_, enzyme_NN expression_NN should_MD not_RB account_VB for_IN the_DT relative_JJ differences_NNS among_IN drugs_NNS in_IN the_DT yeast_NN assay_NN and_CC those_DT in_IN the_DT in_IN vitro_NN assay_NN ,_, which_WDT suggests_VBZ that_IN the_DT abilities_NNS of_IN the_DT drugs_NNS to_TO penetrate_VB the_DT yeast_NN cell_NN wall_NN may_MD differ_VB ._SENT Given_VBN the_DT uncertainty_NN about_IN the_DT ability_NN of_IN various_JJ drugs_NNS to_TO penetrate_VB P._NP carinii_NP compared_VBD to_TO that_DT of_IN yeast_NN ,_, application_NN of_IN these_DT observations_NNS to_TO potential_JJ therapeutic_JJ benefit_NN in_IN the_DT treatment_NN of_IN PCP_NP must_MD be_VB done_VBN cautiously_RB ._SENT It_PP is_VBZ of_IN particular_JJ interest_NN that_IN the_DT human-derived_JJ P._NP carinii_NP DHFR_NP yeast_NN strain_NN showed_VBD an_DT approximately_RB 10-fold_JJ increase_NN in_IN sensitivity_NN to_TO trimetrexate_NP and_CC trimethoprim_NP compared_VBN to_TO that_DT of_IN the_DT rat-derived_JJ P._NP carinii_NP DHFR_NP yeast_NN strain_NN ._SENT Since_IN the_DT host_NN yeast_NN strains_NNS are_VBP identical_JJ ,_, differences_NNS in_IN penetration_NN should_MD not_RB account_VB for_IN the_DT relative_JJ differences_NNS among_IN drugs_NNS demonstrated_VBN by_IN the_DT yeast_NN assay_NN and_CC in_IN vitro_NN assay_NN ._SENT Furthermore_RB ,_, given_VBN that_IN the_DT sensitivities_NNS to_TO pyrimethamine_NN and_CC WR99210_NP were_VBD similar_JJ ,_, it_PP is_VBZ unlikely_JJ that_IN these_DT differences_NNS represent_VBP differential_JJ levels_NNS of_IN enzyme_NN expression_NN in_IN the_DT two_CD yeast_NN strains_NNS ._SENT Rather_RB ,_, as_IN suggested_VBN by_IN the_DT in_IN vitro_NP enzyme_NN inhibition_NN data_NNS ,_, this_DT likely_JJ reflects_VBZ the_DT effects_NNS of_IN the_DT primary_JJ sequence_NN differences_NNS between_IN human-_NN and_CC rat-derived_JJ P._NP carinii_NP DHFRs_NP ._SENT DHFR_NP inhibitors_NNS have_VBP been_VBN among_IN the_DT most_RBS studied_JJ classes_NNS of_IN drugs_NNS for_IN treatment_NN of_IN PCP_NP ._SENT While_IN animal_JJ studies_NNS suggest_VBP that_IN trimethoprim_NP plays_VBZ a_DT minimal_JJ role_NN in_IN the_DT treatment_NN of_IN PCP_NP (_( consistent_JJ with_IN its_PP$ relatively_RB poor_JJ inhibition_NN seen_VBN in_IN this_DT and_CC other_JJ studies_NNS )_) ,_, DHFR_NP inhibitors_NNS such_JJ as_IN trimetrexate_NP clearly_RB have_VBP potent_JJ anti-P_NN ._SENT carinii_NP activity_NN ,_, even_RB as_IN single_JJ agents_NNS ._SENT The_DT present_JJ assay_NN should_MD facilitate_VB identification_NN of_IN additional_JJ potent_JJ and_CC selective_JJ agents_NNS ._SENT Inhibition_NN of_IN DHFR_NP from_IN human-derived_JJ P._NP carinii_NP Inhibition_NP of_IN DHFR_NP from_IN human-derived_JJ P._NP carinii_NP ,_, rat-derived_JJ P._NP carinii_NP ,_, and_CC humans_NNS ,_, by_IN using_VBG S._NP cerevisiae_NNS complemented_VBN by_IN the_DT corresponding_JJ DHFR_NP genes_NNS ._SENT The_DT results_NNS of_IN a_DT representative_JJ IC50_NP assay_NN are_VBP shown_VBN for_IN each_DT drug_NN tested_VBD ._SENT The_DT yeast_NN growth_NN in_IN the_DT control_NN without_IN drug_NN was_VBD scored_VBN as_IN 100_CD %_NN ,_, and_CC the_DT growth_NN of_IN yeast_NN cells_NNS at_IN each_DT drug_NN concentration_NN was_VBD divided_VBN by_IN that_DT of_IN the_DT control_NN to_TO determine_VB the_DT relative_JJ growth_NN ._SENT Each_DT point_NN represents_VBZ the_DT mean_JJ value_NN of_IN triplicate_JJ data_NNS ._SENT Comparison_NN of_IN the_DT IC50s_NP for_IN DHFR_NP inhibitors_NNS obtained_VBN from_IN the_DT yeast_NN complementation_NN assay_NN with_IN those_DT from_IN the_DT in_IN vitro_NN assay_NN 